METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Clinical trials for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could drug holidays improve life for men with advanced prostate cancer?
Disease control Recruiting nowThis study is testing if men with advanced prostate cancer that has spread can safely take planned breaks from their hormone-blocking drugs after their cancer is well-controlled. Researchers want to see if these treatment breaks reduce side effects like fatigue and hot flashes wh…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for prostate cancer patients: experimental drug combo enters clinical testing
Disease control Recruiting nowThis study is testing whether adding a new drug called tulmimetostat to standard prostate cancer treatments can better control the disease in men whose cancer has spread. The first part determines safe doses, and the second part compares the new combination against standard treat…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Japanese study tracks new hope for men with spreading prostate cancer
Disease control Recruiting nowThis study is observing Japanese men with prostate cancer that has spread to a few bones. It aims to learn more about the safety and effectiveness of a three-drug combination treatment they are already receiving from their doctors. Researchers will review medical records to see h…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: Bayer • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New attack on spreading prostate cancer: can zapping the original tumor boost survival?
Disease control Recruiting nowThis study is for men whose prostate cancer has spread to a few other spots in the body but is still sensitive to hormone-blocking drugs. It aims to see if adding a direct treatment to the prostate itself—like surgery or radiation—on top of standard drug therapy is better at keep…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: NA • Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug combo tested in fight against spreading prostate cancer
Disease control Recruiting nowThis early-stage study is testing the safety and side effects of a new drug called xaluritamig when given alongside standard hormone-blocking treatments. It is for men whose prostate cancer has spread and is still responding to hormone therapy. The main goal is to see if the comb…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
Head-to-Head prostate cancer drug showdown: which treatment controls cancer better?
Disease control Recruiting nowThis study compares two medications, rezvilutamide and enzalutamide, for men with prostate cancer that has spread but still responds to hormone-blocking therapy. Both drugs will be given alongside standard hormone treatment to see which one better controls cancer growth and cause…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 02, 2026 15:28 UTC
-
Scientists track hidden side effects of prostate cancer drugs
Knowledge-focused Recruiting nowThis study aims to understand how standard prostate cancer treatments affect patients' thinking, energy levels, mood, and sleep. Researchers will observe 102 men with advanced prostate cancer who are already receiving standard hormone-blocking medications. The study will track ch…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: Ankara Etlik City Hospital • Aim: Knowledge-focused
Last updated Apr 01, 2026 20:11 UTC
-
Massive 5,000-Patient study maps prostate Cancer's Real-World journey
Knowledge-focused Recruiting nowThis study is a large registry that will track 5,000 men in Germany with recurrent or metastatic prostate cancer. Its purpose is to observe and document the real-world treatments doctors choose, how the disease progresses, and how patients' quality of life is affected. It does no…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: UroTrials Company (GmbH) • Aim: Knowledge-focused
Last updated Feb 25, 2026 15:07 UTC